Sign In
Buy ALGS
$5.14
-0.110 (-2.10%)
At Close: Jun 03, 2026
Aligos Therapeutics to Announce First Quarter Results on May 4, 2023
04:05pm, Thursday, 27'th Apr 2023
SOUTH SAN FRANCISCO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on develop
SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates
07:49pm, Thursday, 09'th Mar 2023
Aligos Therapeutics, Inc. (ALGS) delivered earnings and revenue surprises of -4.08% and 26.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the
Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference
07:00am, Friday, 10'th Feb 2023
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
4 Penny Stocks To Buy According To Analysts & Targets Over 600%
09:33am, Wednesday, 25'th Jan 2023
Analysts have put these on their list of penny stocks to buy. Do you agree?
4 Penny Stocks To Buy According To Insiders & Targets Up To 347%
09:29am, Thursday, 19'th Jan 2023
Penny stocks to buy according to analysts. The post 4 Penny Stocks To Buy According To Insiders & Targets Up To 347% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.co
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
04:15pm, Wednesday, 19'th Oct 2022
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, the “Company”), a clinical stage biopharmaceutical company focused on developing novel thera
Aligos' pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023 Aligos' pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2
Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference
04:05pm, Monday, 23'rd May 2022
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u
Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022
04:05pm, Wednesday, 27'th Apr 2022
SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022
04:05pm, Wednesday, 02'nd Mar 2022
SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt
01:49pm, Friday, 07'th Jan 2022
Aligos Therapeutics' (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.
Aligos Therapeutics Stock (ALGS): Why The Price Substantially Fell
09:00am, Friday, 07'th Jan 2022
The stock price of Aligos Therapeutics Inc (NASDAQ: ALGS) fell by 56.74% in the most recent trading session. This is why it happened.
Why Aligos Therapeutics Stock Crumbled Today
06:21pm, Thursday, 06'th Jan 2022
The company is pulling the plug on a once-promising treatment targeting hepatitis B.
